65,437 trials
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Diabetes Mellitus, Type 2
Primary: Number of Neonates With Composite Adverse Neonatal Outcome — 31; 35 Participants
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Adherence to Home Breathing Exercises — 10; 5 Participants
Healthy
Primary: Hemagglutination Inhibition (HI) Antibody Titers as Measured by Hemagglutination Inhibition Assay (HAI) Against Each of the Four Vaccine Influenza Strains — 215; 168…
Cystic Fibrosis
Primary: Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score — 1.2; 17.1 units on a scale — p=< 0.0001
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Response Based on Overall Response Rate — 17; 11; 28; 6 Participants
Age Related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) — 8.1; 7.9 ETDRS Letters
Necrotizing Soft Tissue Infections
Primary: Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period — 14; 16; 9 Participants
Graft-versus-host Disease · Acute-graft-versus-host Disease
Primary: Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT) — 38.4; 47.1…
Healthy Volunteers
Primary: Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype — 149…
Diabetes Mellitus, Type 1
Primary: Percentage of Time in Range: Sensor Glucose Values Between 70-180 mg/dl — 78.4; 75.3 percentage of time — p=0.051
Eosinophilic Gastritis or Gastroenteritis
Primary: Percent of Patients in Histological Remission (<30 Eos/Hpf) — 77; 8 percentage of participants — p=0.0001
Management of Chronic Pain
Primary: Proportion of Subjects Who Are Treatment Failures During the Double-blind Randomized Withdrawal Period — 18; 24 Participants — p=0.147
Primary Immune Deficiency Disorder
Primary: Rate of SBI Per Person-year — 0 SBIs per person year
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale